Feed RCUS
RC

Arcus Biosciences, Inc.

RCUS · NYSE

$24.08 -2.05% (-$0.51)
1M -18.57%
Market Cap $3.03B
P/E Ratio -
Div. Yield -
ROE 87.98%

Bulios Fair Price

$28.14

16.9% upside

Trenutna cena

$24.08

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RCUS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
0/9
Valuation
9 /100
Expensive
P/B 6.53x
P/S 25.89x
EV/FFO N/A
Growth
82 /100
Growing
Book val. growth 1.34%
Rev. growth 30.16%
FCF growth N/A
Profitability
20 /100
Weak
Op. margin 415.39%
Gross margin 94.02%
FCF margin 405.98%
Quality
2 /100
Poor
ROA 48.92%
ROIC 65.76%
Asset turnover 0.13x
Debt
69 /100
Low
Int. coverage -18.65x
Debt/Equity 0.25x
Current ratio 3.82x
Stability
53 /100
Moderate
EPS volatility 19.18%
Beta 0.81x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RCUS
Online

O podjetju

Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Terry J. Rosen

Employees

601

Headquarters

Hayward

Prihajajoči dogodki

27 OKT.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.